allergic rhinitis
Conditions
Interventions
Acupuncture Group:Intransal Acupuncture
Control Group:Oral Loratadine Tablets
Sponsors
Department of Otorhinolaryngology of The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Allergic Rhinitis: 1. Patients who meet the above diagnostic criteria. 2. Aged between 18 and 65 years, regardless of gender. 3. Total Nasal Symptom Score (TNSS) = 4 points. 4. No use of any antibiotics or hormones in the past two months. 5. Patients with no inflammation, polyps, masses, or nasal discharge upon clinical examination of the nostrils (especially the anterior nostrils). 6. No history of nasal surgery or trauma. 7. Patients who seek medical treatment in spring. 8. Voluntarily participate in the trial and sign the informed consent form. Inclusion Criteria for Healthy Volunteers: 1. Aged between 18 and 65 years, regardless of gender. 2. In good health with no diseases. 3. Voluntarily participate in the trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1. Those who have taken H1-antihistamines, steroids, antihistamine preparations, decongestants (acting on the nose, mouth, and eye areas), corticosteroids, antibiotics, or other such drugs within 14 days; those who have received specific immunotherapy or systemic hormone therapy within the past year; those who have undergone physical therapies within the scope of traditional Chinese medicine and other traditional medicines such as acupuncture, moxibustion, cupping, and traditional Chinese medicine inhalation within 14 days; those who have taken traditional Chinese medicine preparations that can affect allergic rhinitis within 14 days or have contraindications to acupuncture. 2. Other types of rhinitis with manifestations such as nasal itching, sneezing, nasal congestion, and nasal discharge caused by non-allergic rhinitis. 3. Those with respiratory tract infections within 14 days before enrollment; those with a history of chronic paranasal sinusitis or diagnosed with chronic paranasal sinusitis through paranasal sinus X-ray examination; nasal polyps; severe nasal septum deviation; those with organic nasal lesions or who have undergone nasal surgery; those with episodic respiratory diseases such as asthma. 4. Complicated with asthma or vasomotor rhinitis. 5. Serum aspartate aminotransferase (AST) > 1.5 times the upper limit of normal, alanine aminotransferase (ALT) > 1.5 times the upper limit of normal, creatinine > upper limit of normal, cystatin C (CysC) > upper limit of normal. 6. Having severe primary cardiovascular diseases, liver diseases, kidney diseases, hematological diseases, lung diseases, or severe diseases affecting survival, such as tumors or AIDS. 7. Pregnant women, women planning to become pregnant, lactating women, psychiatric patients, or legally disabled patients. 8. Those with a suspected or confirmed history of alcohol or drug abuse, or other lesions that, in the investigator's judgment, reduce the possibility of enrollment or complicate enrollment. 9. Patients who have recently participated in other drug clinical trials. 10. Those known to be allergic to the components of this drug. 11. Those who have participated in drug clinical trials within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Nasal and Non-Nasal Symptom Score;Visual Analogue Scale;Metabolomic;Interleukin-4;Interleukin-6;Interleukin-10;Immunoglobulin E;T helper cell type 1;T helper cell type 2;Substance P;Vasoactive Intestinal Peptide;Neuropeptide Y; | — |
Countries
China
Contacts
Public ContactYan Li
The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Outcome results
None listed